Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
ViraBloc
- Development stage
- Unknown
- Lead developer
- HerbalScience Group
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
ViraBloc is a proprietary, patent-pending elderberry (*Sambucus nigra*) extract developed by HerbalScience Group. Classified as a nutraceutical or dietary supplement rather than a pharmaceutical drug, it is marketed to support immune health and provide defense against viral infections, particularly influenza. The extract is produced using a specialized extraction technology designed to concentrate specific polyphenols and anthocyanins. Its primary mechanism of action involves inhibiting viral entry into host cells by blocking the attachment of viral particles to cell surfaces. ViraBloc has been commercialized in various formats, including lozenges, and has been featured in products such as New Chapter's "Blockade" and sold through retailers like GNC.
- Brand names
- ViraBlocNuHerbal ViraBloc
- Other names
- elderberry extract
Beyond the preview
Go deeper on ViraBloc.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on ViraBloc.